Skip to main content

Day: December 19, 2024

FactSet Reports Results for First Quarter 2025

Q1 GAAP revenues of $568.7 million, up 4.9% from Q1 2024. Organic Q1 ASV of $2,258.8 million, up 4.5% year over year. Q1 GAAP operating margin of 33.6%, down approximately 120 bps year over year, and adjusted operating margin of 37.6%, consistent with the prior year. Q1 GAAP diluted EPS of $3.89, up 1.3% from the prior year, and adjusted diluted EPS of $4.37, up 6.1% year over year.NORWALK, Conn., Dec. 19, 2024 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced results for its first quarter fiscal 2025 ended November 30, 2024. First Quarter Fiscal 2025 HighlightsGAAP revenues increased 4.9%, or $26.5 million, to $568.7 million for the first quarter of fiscal 2025 compared with $542.2 million in the prior year...

Continue reading

Western Investment Company Closes Outstanding $1.1 Million of the $30 Million Over-Subscribed Private Placement

CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) — The Western Investment Company of Canada Limited (TSXV: WI) (“Western” or “WICC“), today closed the over-subscribed private placement announced on August 30, 2024, and upsized on September 26, 2024, in its entirety following the receipt of $1.1 million that was outstanding. Unless otherwise indicated, financial figures are expressed in Canadian dollars. On August 30, 2024 WICC announced a private placement of units (“Units”) that was subsequently upsized on September 26, 2024 to $25 million, with an additional $5 million over-allotment at Western’s option, for aggregate gross proceeds of $30 million (the “Private Placement”). In aggregate, WICC has issued 75,000,000 Units in the Private Placement for gross proceeds of $30 million (including the 2,750,000...

Continue reading

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company’s approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management (“Petrichor”). Pro forma for today’s announced repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity of September 2027. This early partial repayment was financed entirely with available cash. “We are pleased to announce the early partial repayment...

Continue reading

Aktsiaselts Infortar subsidiary AS Elenger Grupp received an approval from Competition Authority to acquire a shareholding in EWE Polska

AS Elenger Grupp (Elenger Grupp), a wholly owned subsidiary of Aktsiaselts Infortar (Infortar) and the German energy group EWE AG have entered into an agreement on the 31st of October 2024, under which EWE AG will sell 100% of the shares of its wholly owned subsidiary EWE Polska sp. z o.o. (EWE Polska) which operates in Poland. EWE Polska has two wholly owned subsidiaries, EWE Energia sp. z o.o. and EWE Przesył sp. z o.o. . Polish Competition Authority (Polish: Urząd Ochrony Konkurencji i Konsumentów) has granted a merger permit to complete the transaction and after fulfilment other preconditions, today Elenger Grupp acquired a 100% shareholding in EWE Polska. The main terms of the transaction for the acquisition of 100% of EWE Polska shares by Elenger Grupp, including the purchase price, are set out in the stock exchange release by Infortar...

Continue reading

Rackspace Technology Signs UK Armed Forces Covenant, Reinforcing Commitment to Veterans and the UK Public Sector

Pledge highlights Rackspace dedication to supporting those who serve or have served in the Armed Forces, and their families LONDON, Dec. 19, 2024 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a leading provider of end-to-end hybrid, multicloud and AI technology solutions, is proud to announce its formal commitment to the UK Armed Forces by signing the Armed Forces Covenant. This pledge highlights Rackspace Technology’s dedication to supporting those who serve or have served in the Armed Forces, and their families. The Armed Forces Covenant ensures that those who serve or have served in the armed forces, and their families, are treated fairly. By signing this Covenant, Rackspace Technology pledges to uphold the key principles of the Covenant, supporting the employment of veterans, service spouses, and partners, and offering...

Continue reading

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris, 19 December 2024 – 10.30am Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible) and EB Development announce the final outcome of the takeover bid initiated by EB Development (the “Offer“), based on the results published on 18 December by the Autorité des marchés financiers (AMF) at the end of the reopening period of the Offer (the “Reopened Offer“). 644,911 ordinary shares were tendered to the Reopened Offer, which closed on 17 December 2024. These are in addition to the 4,582,971 ordinary shares tendered to the Initial Offer, giving a total of 5,227,882 ordinary shares tendered to the Offer, enabling EB...

Continue reading

Share Buyback Transaction Details December 12 – December 18, 2024

PRESS RELEASE                                         Share Buyback Transaction Details December 12 – December 18, 2024 Alphen aan den Rijn – December 19, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 116,200 of its own ordinary shares in the period from December 12, 2024, up to and including December 18, 2024, for €18.9 million and at an average share price of €162.95. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share...

Continue reading

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

Strengthened Pipeline Targets Multiple Fibrotic Diseases MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces the acquisition of OccuRx, a Melbourne-based biotechnology company with highly complementary assets, resources and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis. The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor Darren Kelly, consolidating a pipeline that now includes two Phase 2 and one Phase 1 clinical candidates. Building on Professor Kelly’s pioneering research into inhibitors of GPR68 and benefiting from years of further development within biotechnology and major pharma...

Continue reading

Prosafe SE: Operational update – November 2024

19 December – Fleet utilisation for November 2024 was 57 per cent.   In November, all operating vessels – Safe Notos, Safe Eurus, Safe Zephyrus and Safe Concordia – achieved 100 per cent utilisation. Safe Zephyrus extension into Q3 2027 expected with Petrobras. Safe Caledonia has commenced reactivation activities in Scapa Flow, UK, and will mobilise to the Captain Field, UK, within June 2025. Safe Boreas is laid up in Norway pending relocation in Q2 2025 for a contract in Australia commencing earliest October 2025. The reactivation process is ongoing. Safe Scandinavia is laid up in Norway. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com For further information,...

Continue reading

Suspension of Listing

Albion KAY VCT PLC (LEI: 213800DK8H27QY3J5R45) (Company) Prior to a resolution to cancel the listing of the Company’s shares on the Official List of the Financial Conduct Authority, which will be put to the Company’s shareholders at a general meeting of the Company to be held on 19 December 2024, trading in the Company’s shares has now been suspended. For further information, please contact: Vikash Hansrani Operations Partner Albion Capital Group LLP Company Secretary Telephone: 020 7601 1850

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.